Stock Evaluator: Interpace Biosciences, Inc. (IDXGD)
Interpace Biosciences, Inc. IDXGD
$6.91
0.40
6.18%
September 4, 2026 3:58:43 PM
EST
Volume: 3,270
After Hours: $120.37
0.15
|
0.12%
November 10, 2021 7:59 PM
EST
Volume: 72,713
USD
| DELAYED PRICE
| SECTOR | INDUSTRY |
| Health Care | Health Care Providers & Services |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Interpace Biosciences, Inc. provides molecular diagnostic tests and pathology services for evaluating cancer risk in the United States. It offers ThyGeNEXT, an oncogenic mutation panel to identify malignant thyroid nodules. The company also provides ThyraMIR v2, which assesses thyroid nodules for malignancy risk using a proprietary microRNA gene expression classifier. It primarily serves physicians, cancer centers, clinics, laboratories, pathology groups, and hospitals. The company was formerly known as Interpace Diagnostics Group, Inc. and changed its name to Interpace Biosciences, Inc. in November 2019. Interpace Biosciences, Inc. was incorporated in 1986 and is headquartered in Parsippany, New Jersey.
Financial Summary
| Share Statistics | IDXGD | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $38.3 | $1,785.4 | 14% |
|
| Shares Out (Mil) | 5.5 | 71.5 | 15% |
|
| Institutional Ownership | 5.2% | 86.0% | 5% |
|
| Float (Mil) | 0.4 | 55.7 | 1% |
|
| Beta | 0.61 | 0.74 | 36% |
|
| Avg Daily Volume (000s) | 6 | 402 | 15% |
|
| Price Change (52-week) |
63.5% | 78.5% | 85% |
|
| Growth | IDXGD | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 3.6% | 10.7% | 30% |
|
| Net Income (5yr) | 24.0% | (0.5%) | 79% |
|
| EPS (5yr) | 16.2% | 2.1% | 60 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (1.9%) | (17.5%) | 63% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | IDXGD | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $36 | $1,490 | 17% |
|
| Net Income (TTM) (Mil) | $24 | $24 | 50% |
|
| EPS (TTM) | $8.367 | $0.200 | 93% |
|
| Operating Cash Flow (TTM) (Mil) | $5 | $151 | 36% |
|
| Net Cash Flow (TTM) (Mil) | na | $9 | na |
|
| Long-Term Debt (Q1) (Mil) | $1 | $338 | 15% |
|
| Enterprise Value (Q1) (Mil) | $41 | $2,334 | 15% |
|
| Valuation | IDXGD | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.96 | na |
|
| P/E | na | 25.5 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | IDXGD | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 63.7% | 27.9% | 76% |
|
| Net Margin | 67.6% | 1.3% | 98% |
|
| ROA | 104.3% | 2.2% | 100% |
|
| ROE | 221.9% | 6.8% | 98% |
|
| Liabilities to Assets | 32.7% | 60.5% | 24% |
|
| F-Score | na | 5 | na |
|
Interpace Biosciences, Inc. did not pass any screens on 9/4/2026.
